caa a22 4500 445338660 CHVBK 20180317142804.0 cr unu---uuuuu 170323e20111201xx s 000 0 eng 10.1245/s10434-011-1657-8 doi (NATIONALLICENCE)springer-10.1245/s10434-011-1657-8 Basal-Like Breast Cancer Defined by FOXC1 Expression Offers Superior Prognostic Value: A Retrospective Immunohistochemical Study [Elektronische Daten] [Partha Ray, Sanjay Bagaria, Jinhua Wang, Jaime Shamonki, Xing Ye, Myung-Shin Sim, Shawn Steen, Ying Qu, Xiaojiang Cui, Armando Giuliano] Background: Basal-like breast cancer (BLBC) has a poor prognosis and is often identified by the triple-negative phenotype (TNP) and/or basal cytokeratins (CKs). Overexpression of mRNA for forkhead box C1 (FOXC1) transcription factor was recently identified as a pivotal prognostic biomarker of BLBC. We investigated the prognostic value of FOXC1 protein expression in invasive breast cancer and compared its prognostic significance to that of TNP and basal CKs. Methods: Archived TNP specimens of primary invasive ductal breast cancer from 759 patients were examined by immunohistochemical staining for FOXC1, CK5/6, and CK14; prognostic significance was assessed using multivariate analyses. In addition, the impact of adding FOXC1 versus basal CKs to TNP-based BLBC assessment was assessed. Results: FOXC1 protein expression was a significant predictor of overall survival on univariate (hazard ratio [HR] 3.364 95% confidence interval [CI] 1.758-6.438, P=0.0002) and multivariate (HR 3.389 95% CI 1.928-7.645, P=0.0001) analyses, despite its correlation with younger age (P=0.0003). Interestingly, nodal status was not significant on multivariate analysis when FOXC1 expression status was included in the analysis. BLBC defined by TNP plus FOXC1 demonstrated superior prognostic relevance compared to BLBC defined by TNP or TNP plus basal CKs. Conclusions: Immunohistochemical detection of FOXC1 expression in TNP invasive breast cancer is an independent prognostic indicator that is superior to conventional immunohistochemical surrogates of BLBC. Prospective validation is warranted to further define the diagnostic, prognostic, and predictive utility of FOXC1 in breast cancer management and clinical trial design. Society of Surgical Oncology, 2011 Ray Partha Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Bagaria Sanjay Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Wang Jinhua Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Shamonki Jaime Department of Pathology, Saint John's Health Center, Santa Monica, CA, USA aut Ye Xing Department of Biostatistics, John Wayne Cancer Institute, Santa Monica, CA, USA aut Sim Myung-Shin Department of Biostatistics, John Wayne Cancer Institute, Santa Monica, CA, USA aut Steen Shawn Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Qu Ying Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Cui Xiaojiang Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Giuliano Armando Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3839-3847 1068-9265 18:13<3839 2011 18 10434 https://doi.org/10.1245/s10434-011-1657-8 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1245/s10434-011-1657-8 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Ray Partha Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Bagaria Sanjay Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Wang Jinhua Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Shamonki Jaime Department of Pathology, Saint John's Health Center, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Ye Xing Department of Biostatistics, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Sim Myung-Shin Department of Biostatistics, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Steen Shawn Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Qu Ying Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Cui Xiaojiang Department of Molecular Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 700 1- Giuliano Armando Department of Surgical Oncology, John Wayne Cancer Institute, Santa Monica, CA, USA aut NATIONALLICENCE 773 0- Annals of Surgical Oncology Springer-Verlag 18/13(2011-12-01), 3839-3847 1068-9265 18:13<3839 2011 18 10434 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer